ODDB.org: Open Drug Database | Medikamente

Home - FI zu Syntocinon® Konzentrat zur Herstellung einer Injektions-/Infusionslösung; Syntocinon® Nasenspray, Lösung

Fachinformation zu Syntocinon® Konzentrat zur Herstellung einer Injektions-/Infusionslösung; Syntocinon® Nasenspray, Lösung:

Exeltis Suisse SA

H01BB02 - Oxytocin

ATC-DDD Version 2016. Source: WHO

H - Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.

H01 - Pituitary and Hypothalamic Hormones and Analogues

H01B - Posterior Pituitary Lobe Hormones

This group comprises posterior pituitary lobe hormones; extracts, purified natural hormones and synthetic analogues.

H01BB - Oxytocin and Analogues

Oxytocin and analogues in combination with ergot alkaloids are classified in G02A - Uterotonics

The DDDs are based on use in delivery.

H01BB02 - Oxytocin

Stärke	Adm.Route	Note
	P
	O
	N

2025	©ywesee GmbH